ParagaonDx

Publications and Presentations

ParagonDx Receives 510(k) Marketing Clearance for Warfarin Sensitivity Genotyping Kit

PDFFDA 510(k) marketing clearance for warfarin sensitivity genotyping kit
PDFFDA official letter of April 28, 2008

Why is there not a de facto gold standard for genetic-testing controls? (Article in Medical Laboratory Observer May 2008)

PDFWhy is there not a de facto gold standard for genetic-testing controls?

Recent New Items

PDFHuman Genomic Reference Control Brochure
PDFProficiency Testing Flyer
PDFWarfarin Metabolism and Sensitivity--Diagnostic RT-PCR Assay for 2C9 and VKORC1--AMP 2007
PDFComparison of ParagonDx Human Genomic Quality Controls and Coriell DNA--AMP 2007

Previous Publications and Presentations

PDFParagonDx Formation Press Release
PDFWhite Paper on Reference Controls for In Vitro Diagnostics
PDFParagonDx Provides Genetic Testing to CED Tech 2007 Attendees
PDFHuman Genomic DNA Reference Controls for PGx Testing--AMP 2006
PDFPrediction of Warfarin Metabolism--AMP 2006
PDFGenotyping Comparison between Blood and Saliva DNA--CYP2C9 & VKORC1--AMP 2006
PDFCYP2D6 Human Genomic Reference Controls Derived from EBV-transformed Cell Lines--AACC 2006
PDFCYP2E1 & CYP3A4 SNPs & Relationships to mRNA Levels in Peripheral Blood Lymphocytes

Pursuing a Common Goal - In Person with Michael P. Murphy
IVD Technology, January-February 2006

Testing in the Age of Genetics
Triangle Business Journal, December 19, 2005

Pharmacogenomic Testing: Clinical Diagnostic Laboratories
AACC Expert Access 
Presented by: Michael P. Murphy, M.Sc.

The Heat is On - How long can the U.S. maintain its innovative edge?
Entrepreneur Magazine, November 2005

PDFAssay Design May Affect Genotyping Results for the CYP2D6 C188T Polymorphism-- Environmental Mutagen Society Annual Meeting
PDFProspective CYP2D6 genotyping as an exclusion criteria for enrollment of a phase III clinical trial--Pharmacogenetics 10:583-590, 2000
PDFComparative Methods for SNP Analysis of CYP450s--Drug Discovery Technology Annual Meeting 2005
PDFAllelic Frequencies and Ethnic Associations with CYP2C8 -- Drug Discovery Technology 2005 Annual Meeting
PDFPharmacogenomics--a critical component of patient stratification during drug development- Michael P. Murphy, M.Sc., Future Drugs Ltd.,2002
PDFCurrent pharmacogenomic approaches to clinical drug development -Michael P. Murphy, M.Sc., Pharmacogenomics-2000
PDFPharmacogenomics--a new paradigm for drug development - Michael P. Murphy, M.Sc.-- Pharmacogenomics-2000
PDFCharacterization of duplicated CYP2D6 alleles--Correlation with ethnicity--ASCPT 2006

© 2007, ParagonDx.